The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
01-Jul-20
$225 million
Target:
Cello Health plc
Acquiror:
Arsenal Capital Partners
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
10-Jun-20
$134 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
02-Mar-20
$NA
Target:
Global rights (excluding North America) to ThermaCare (United Kingdom)
Acquiror:
Angelini Pharma
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
20-Feb-20
$NA
Target:
Asia and US rights to Physiogel
Acquiror:
LG Household & Health Care
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
16-Jan-20
$NA
Target:
Daimler's Mercedes-Benz passenger car and private vans distribution operations in Colombia
Acquiror:
Inchcape PLC
Advised Inchcape, a leading global independent multi-brand automotive distributor, on its acquisition of the Mercedes-Benz passenger car and private vans distribution operations in Colombia from Daimler Colombia
10-Jul-19
$NA
Target:
ICC Brazil
Acquiror:
Lallemand
Advised ICC Brazil, the leader in animal health and nutrition ingredients derived from yeast in Brazil, on establishing a long term strategic partnership with Lallemand, a global leader in the development, production and marketing of yeast, bacteria and specialty ingredients
17-Jun-19
$80 million
Target:
Renewi Canada
Acquiror:
Convent Capital
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
19-Dec-18
$NA
Target:
Pfizer Inc. Consumer Health Business
Acquiror:
GlaxoSmithKline plc
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
03-Dec-18
$4.0 billion
Target:
Assets owned by GlaxoSmithKline plc
Acquiror:
Unilever plc / Hindustan Unilever Limited
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
30-Jul-18
$435 million
Target:
Berger Group Holdings, Inc.
Acquiror:
WSP Global Inc.
Advised Berger Group Holdings, Inc. (“Louis Berger”), a leading international professional services engineering firm, on its sale to WSP Global Inc.
13-May-18
$81 million
Target:
GWA Group Limited’s Door and Access Controls Business
Acquiror:
Allegion plc
Advised Allegion plc, a leading global security products and solutions provider, on the acquisition of GWA Group Limited’s Door & Access Systems Business, a leading provider of door furniture and commercial locksmith services in Australia
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
26-May-17
$415 million
Target:
Chromalox
Acquiror:
Spirax Sarco
Advised Chromalox, a leading provider of electrical products, systems and solutions for industrial process heating and temperature management, on its sale to Spirax Sarco, a global engineering group
11-May-17
$245 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
25-Apr-16
$3.4 billion
Target:
Divestment assets of Ball and Rexam
Acquiror:
Ardagh Group SA
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam
01-Dec-15
$164 million
Target:
Incotec Group BV
Acquiror:
Croda International Plc
Advised Croda International Plc, a leading UK listed global specialty chemicals producer, on its acquisition of Incotec Group BV, a Netherlands based provider of seed enhancement technologies
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
02-Nov-15
$NA
Target:
Reaction Engines Limited
Acquiror:
BAE Systems plc
Advised Reaction Engines Limited, a privately-held company located in the United Kingdom, on a strategic investment by BAE Systems plc, a leading defense, security and aerospace company based in the United Kingdom, to accelerate the company’s development of a new aerospace engine class
28-Oct-15
$NA
Target:
DataLase Ltd
Acquiror:
Sato Holdings Corporation
Advised Sato Holdings Corporation, a leading global provider of Auto-ID solutions, on its acquisition of a significant minority stake in DataLase Ltd, a UK-based provider of materials for laser coding and marking of products and packaging